This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
<i>Fibroblast growth factor receptor (FGFR) fusions associated with multiple cancer types</i>	<p>Patient sample and mouse studies identified <i>FGFR</i> fusions in multiple cancers and suggest inhibiting such targets could have therapeutic benefit. Activating mutations and amplifications of <i>FGFR</i> have previously been identified as drivers in many cancers. In multiple cancer types including bladder, breast and prostate cancer, rearrangements in <i>FGFR</i> were identified. In xenograft mice with bladder cancer cells carrying <i>FGFR3</i> (<i>CD333</i>) fusions, a small molecule FGFR inhibitor decreased tumor growth compared with vehicle. Next steps could include screening additional cancers for <i>FGFR</i> fusions.</p> <p>At least six selective FGFR inhibitors are in Phase II testing or earlier to treat various cancers.</p> <p>SciBX 6(16); doi:10.1038/scibx.2013.404 Published online April 25, 2013</p>	Patent and licensing status unavailable	<p>Wu, Y.-M. <i>et al. Cancer Discov.</i>; published online April 4, 2013; doi:10.1158/2159-8290.CD-13-0050</p> <p>Contact: Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Mich. e-mail: arul@umich.edu</p>